发布求助
文献互助 智能选刊 最新文献

Trends in cancer最新文献

筛选
英文 中文
Prognostic value of atypical B cells in breast cancer. 乳腺癌非典型 B 细胞的预后价值。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-11-01 Epub Date: 2024-10-01 DOI: 10.1016/j.trecan.2024.09.009
Esmeralda García-Torralba, Lorenzo Galluzzi, Aitziber Buqué
{"title":"Prognostic value of atypical B cells in breast cancer.","authors":"Esmeralda García-Torralba, Lorenzo Galluzzi, Aitziber Buqué","doi":"10.1016/j.trecan.2024.09.009","DOIUrl":"10.1016/j.trecan.2024.09.009","url":null,"abstract":"<p><p>The impact of tumor-infiltrating B cells on breast cancer (BRCA) outcomes remains poorly understood. Recent findings from Yang et al. identify an atypical, clonally expanded population of activated Fc receptor-like 4 (FCRL4)<sup>+</sup> B cells that is associated with improved overall survival in patients affected by various tumor types, including BRCA.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"990-991"},"PeriodicalIF":14.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accessing the vasculature in cancer: revising an old hallmark. 进入癌症血管：重新审视古老的标志。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-11-01 Epub Date: 2024-10-02 DOI: 10.1016/j.trecan.2024.08.003
Adrian L Harris, David J Kerr, Francesco Pezzella, Domenico Ribatti
{"title":"Accessing the vasculature in cancer: revising an old hallmark.","authors":"Adrian L Harris, David J Kerr, Francesco Pezzella, Domenico Ribatti","doi":"10.1016/j.trecan.2024.08.003","DOIUrl":"10.1016/j.trecan.2024.08.003","url":null,"abstract":"<p><p>The classic cancer hallmark, inducing angiogenesis, was born out of the long-held notion that tumours could grow only if new vessels were formed. The attempts, based on this premise, to therapeutically restrain angiogenesis in hopes of controlling tumour growth have been less effective than expected. This is partly because primary and metastatic tumours can grow without angiogenesis. The discovery of nonangiogenic cancers and the mechanisms they use to exploit normal vessels, called 'vessel co-option,' has opened a new field in cancer biology. Consequently, the cancer hallmark, 'inducing angiogenesis,' has been modified to 'inducing or accessing vasculature.'</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"1038-1051"},"PeriodicalIF":14.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time to heal: inhibiting fibrosis prevents glioblastoma recurrence. 愈合时间：抑制纤维化可预防胶质母细胞瘤复发。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-11-01 Epub Date: 2024-10-02 DOI: 10.1016/j.trecan.2024.09.008
Dhanashree Mundhe, Neta Erez
{"title":"Time to heal: inhibiting fibrosis prevents glioblastoma recurrence.","authors":"Dhanashree Mundhe, Neta Erez","doi":"10.1016/j.trecan.2024.09.008","DOIUrl":"10.1016/j.trecan.2024.09.008","url":null,"abstract":"<p><p>New findings by Watson et al. demonstrate that therapy-induced inflammation and fibrosis potentiate glioblastoma recurrence. Post-treatment fibrotic niches shielded surviving tumor cells from immune surveillance, supported their persistence in a dormant state, and enabled rebound growth. Timely inhibition of inflammation and scarring attenuated recurrence, encouraging the use of new combinatorial approaches in glioblastoma therapy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"987-989"},"PeriodicalIF":14.3,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence. 缺氧癌细胞新陈代谢的转录调控与人工智能。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-10-30 DOI: 10.1016/j.trecan.2024.10.003
Luana Schito, Sergio Rey-Keim
{"title":"Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence.","authors":"Luana Schito, Sergio Rey-Keim","doi":"10.1016/j.trecan.2024.10.003","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.10.003","url":null,"abstract":"<p><p>Gene expression regulation in hypoxic tumor microenvironments is mediated by O<sub>2</sub> responsive transcription factors (O<sub>2</sub>R-TFs), fine-tuning cancer cell metabolic demand for O<sub>2</sub> according to its availability. Here, we discuss key O<sub>2</sub>R-TFs and emerging artificial intelligence (AI)-based applications suitable for the interrogation of O<sub>2</sub>R-TF relationships specifying cancer cell metabolic adaptations to hypoxia.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition. 抗 PD-1/PD-L1 免疫疗法的新增强剂：PCSK9 抑制剂
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-10-24 DOI: 10.1016/j.trecan.2024.10.002
Shengbo Sun, Zhengyang Yang, Hongwei Yao, Zhongtao Zhang
{"title":"A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition.","authors":"Shengbo Sun, Zhengyang Yang, Hongwei Yao, Zhongtao Zhang","doi":"10.1016/j.trecan.2024.10.002","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.10.002","url":null,"abstract":"<p><p>Anti-programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) immunotherapy has shown promising results in cancer treatment, improving clinical outcomes and prolonging patient survival. However, most patients exhibit low response rates to PD-1/PD-L1 blockade, highlighting the urgent need for new enhancers. Increasing data now demonstrate that inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine proteinase, can enhance the antitumor efficacy of anti-PD-1/PD-L1 immunotherapy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142508856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity. 小细胞肺癌特征分析：亚型、脆弱性和可塑性的最新综述。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-10-01 Epub Date: 2024-08-19 DOI: 10.1016/j.trecan.2024.07.008
Esther Redin, Álvaro Quintanal-Villalonga, Charles M Rudin
{"title":"Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity.","authors":"Esther Redin, Álvaro Quintanal-Villalonga, Charles M Rudin","doi":"10.1016/j.trecan.2024.07.008","DOIUrl":"10.1016/j.trecan.2024.07.008","url":null,"abstract":"<p><p>Small cell lung cancer (SCLC) is a devastating disease with high proliferative and metastatic capacity. SCLC has been classified into molecular subtypes based on differential expression of lineage-defining transcription factors. Recent studies have proposed new subtypes that are based on both tumor-intrinsic and -extrinsic factors. SCLC demonstrates substantial intratumoral subtype heterogeneity characterized by highly plastic transcriptional states, indicating that the initially dominant subtype can shift during disease progression and in association with resistance to therapy. Strategies to promote or constrain plasticity and cell fate transitions have nominated novel targets that could prompt the development of more durably effective therapies for patients with SCLC. In this review, we describe the latest advances in SCLC subtype classification and their biological and clinical implications.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"935-946"},"PeriodicalIF":14.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142009523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CFTR and colorectal cancer susceptibility: an urgent need for further studies. CFTR 与结直肠癌易感性：迫切需要进一步研究。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-10-01 Epub Date: 2024-08-14 DOI: 10.1016/j.trecan.2024.07.006
S Spelier, S Derksen, R Hofland, J M Beekman, B Yetkin-Arik
{"title":"CFTR and colorectal cancer susceptibility: an urgent need for further studies.","authors":"S Spelier, S Derksen, R Hofland, J M Beekman, B Yetkin-Arik","doi":"10.1016/j.trecan.2024.07.006","DOIUrl":"10.1016/j.trecan.2024.07.006","url":null,"abstract":"<p><p>Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in cystic fibrosis, a multiorgan disease characterized by aberrant epithelial cell fluid secretion. Recent studies describe a connection between CFTR malfunctioning and a heightened susceptibility to colorectal cancer (CRC). Here, we outline these links and suggest directions for further studies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"876-879"},"PeriodicalIF":14.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in exosomes utilization for clinical applications in cancer. 外泌体在癌症临床应用中的应用进展。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-10-01 Epub Date: 2024-08-20 DOI: 10.1016/j.trecan.2024.07.010
Inês A Batista, José C Machado, Sonia A Melo
{"title":"Advances in exosomes utilization for clinical applications in cancer.","authors":"Inês A Batista, José C Machado, Sonia A Melo","doi":"10.1016/j.trecan.2024.07.010","DOIUrl":"10.1016/j.trecan.2024.07.010","url":null,"abstract":"<p><p>Exosomes are regarded as having transformative potential for clinical applications. Exosome-based liquid biopsies offer a noninvasive method for early cancer detection and real-time disease monitoring. Clinical trials are underway to validate the efficacy of exosomal biomarkers for enhancing diagnostic accuracy and predicting treatment responses. Additionally, engineered exosomes are being developed as targeted drug delivery systems that can navigate the bloodstream to deliver therapeutic agents to tumor sites, thus enhancing treatment efficacy while minimizing systemic toxicity. Exosomes also exhibit immunomodulatory properties, which are being harnessed to boost antitumor immune responses. In this review, we detail the latest advances in clinical trials and research studies, underscoring the potential of exosomes to revolutionize cancer care.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"947-968"},"PeriodicalIF":14.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The origin of novel traits in cancer. 癌症新性状的起源
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-10-01 Epub Date: 2024-08-06 DOI: 10.1016/j.trecan.2024.07.005
Steven A Frank, Itai Yanai
{"title":"The origin of novel traits in cancer.","authors":"Steven A Frank, Itai Yanai","doi":"10.1016/j.trecan.2024.07.005","DOIUrl":"10.1016/j.trecan.2024.07.005","url":null,"abstract":"<p><p>The traditional view of cancer emphasizes a genes-first process. Novel cancer traits arise by genetic mutations that spread to drive phenotypic change. However, recent data support a phenotypes-first process in which nonheritable cellular variability creates novel traits that later become heritably stabilized by genetic and epigenetic changes. Single-cell measurements reinforce the idea that phenotypes lead genotypes, showing how cancer evolution follows normal developmental plasticity and creates novel traits by recombining parts of different cellular developmental programs. In parallel, studies in evolutionary biology also support a phenotypes-first process driven by developmental plasticity and developmental recombination. These advances in cancer research and evolutionary biology mutually reinforce a revolution in our understanding of how cells and organisms evolve novel traits in response to environmental challenges.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"880-892"},"PeriodicalIF":14.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bispecific antibodies: advancing precision oncology. 双特异性抗体：推动精准肿瘤学的发展。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2024-10-01 Epub Date: 2024-08-30 DOI: 10.1016/j.trecan.2024.07.002
Mercedes Herrera, Giulia Pretelli, Jayesh Desai, Elena Garralda, Lillian L Siu, Thiago M Steiner, Lewis Au
{"title":"Bispecific antibodies: advancing precision oncology.","authors":"Mercedes Herrera, Giulia Pretelli, Jayesh Desai, Elena Garralda, Lillian L Siu, Thiago M Steiner, Lewis Au","doi":"10.1016/j.trecan.2024.07.002","DOIUrl":"10.1016/j.trecan.2024.07.002","url":null,"abstract":"<p><p>Bispecific antibodies (bsAbs) are engineered molecules designed to target two different epitopes or antigens. The mechanism of action is determined by the bsAb molecular targets and structure (or format), which can be manipulated to create variable and novel functionalities, including linking immune cells with tumor cells, or dual signaling pathway blockade. Several bsAbs have already changed the treatment landscape of hematological malignancies and select solid cancers. However, the mechanisms of resistance to these agents are understudied and the management of toxicities remains challenging. Herein, we review the principles in bsAb engineering, current understanding of mechanisms of action and resistance, data for clinical application, and provide a perspective on ongoing challenges and future developments in this field.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"893-919"},"PeriodicalIF":14.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信